Ulcerative Colitis | Unmet Need | US/EU | 2018

Publish date: March 2018

Login to access report

MARKET OUTLOOK

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for [[indication]]?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for [[indication]]?
  • What are the prevailing areas of unmet need and opportunity in [[indication]]?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European [[physician type, plural]] for a hypothetical new [[indication]] drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of [[XX]] U.S. and [[XX]] European [[physician type, plural]] fielded in [[Month. Year]]

Key companies: [[key company 1]], [[key company 2]], [[key company 3]]

Key drugs: [[key drug 1]], [[key drug 2]], [[key drug 3]]